10月13日早间重要公告一览

Group 1 - Guangqi Technology's subsidiary signed mass production contracts for metamaterials totaling 516 million yuan, with products to be delivered by June 30, 2026 [1][2] - Mingyang Smart Energy plans to invest 1.5 billion pounds (approximately 14.21 billion yuan) to build a comprehensive wind power manufacturing base in Scotland, with the first phase expected to be operational by the end of 2028 [3][4] - Wentech Technology's control over Anshi Semiconductor is temporarily restricted due to a ministerial order from the Dutch government, affecting operational efficiency but not economic benefits [4][5] Group 2 - Baotailong's mine has officially resumed production with an annual design capacity of 900,000 tons [6] - New Lai Materials reported no significant changes in its operating environment, maintaining normal production and operations [7][8] - Tailing Micro plans to issue H-shares and list on the Hong Kong Stock Exchange [9] Group 3 - Times New Material announced a cash dividend of 0.07 yuan per share, totaling 65.18 million yuan, with the ex-dividend date set for October 17, 2025 [10] - Times New Material signed blade sales contracts totaling approximately 4.49 billion yuan, with 4.048 billion yuan from onshore wind projects and 442 million yuan from offshore projects [11][12] - Sunshine Nuohuo's new drug BTP4507 has received approval for clinical trials, targeting patients with poorly controlled primary hypertension [13] Group 4 - BGI Genomics expects to receive over 120 million USD in licensing fees for its CoolMPS sequencing technology [14] - Shandong Environmental Energy won a project for kitchen waste treatment in Xingtai, with an 8-year service period [15] - Kelun Pharmaceutical's product sac-TMT received approval for a third indication for treating advanced non-small cell lung cancer [16] Group 5 - Zhongzhi Holdings' major shareholder plans to publicly transfer 24.73% of the company's shares, which may lead to a change in control [17] - Yunnan Copper reported uncertainty regarding the future prices of cathode copper and gold, while maintaining normal operations [18] - Xiyang Co. announced that its tin smelting processing fees remain low despite rising tin prices [19] Group 6 - TEBIO's product Peginterferon has received approval for an additional indication for chronic hepatitis B treatment [20] - Yirui Biotech's major shareholder plans to reduce their stake by up to 3% due to personal funding needs [21] - China Nuclear Power reported a 14.95% year-on-year increase in power generation for the first three quarters, totaling 184.364 billion kWh [22] Group 7 - Shanghai Hejing's shareholder plans to reduce their stake by up to 1% due to personal funding needs [23] - Baili Tianheng's subsidiary triggered a milestone payment of 250 million USD from a collaboration with Bristol-Myers Squibb [24] - Hengdian East Magnetic expects a net profit increase of 50.1% to 65.2% year-on-year for the first three quarters [25]